Paper Details

  1. Home
  2. Paper Details

Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.

Author: ChinoTatsunori, ItoKen-Ichi, ItoTokiko, KanaiToshiharu, MaenoKazuma, ObaTakaaki, OnoMayu, ShimizuTadafumi, SomaAi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This meta-analysis assessed the efficacy and toxicity of four tyrosine kinase inhibitors (TKIs) used for thyroid cancer treatment. The authors highlight the differences in their clinical efficacy and toxicity profiles, suggesting that each TKI may be more suitable for specific types of thyroid cancer.
Paper Details　
Original Abstract of the Article :
The tyrosine kinase inhibitors (TKIs) sorafenib, lenvatinib, vandetanib, and cabozantinib are currently used for thyroid cancer treatment; however, the differences in their clinical efficacy and toxicity remain unclear. This meta-analysis assessed the efficacy and toxicity of these four TKIs based o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1507/endocrj.EJ20-0171

データ提供：米国国立医学図書館（NLM）

Tyrosine Kinase Inhibitors for Thyroid Cancer: A Comparative Analysis

This meta-analysis compares the effectiveness and side effects of different tyrosine kinase inhibitors (TKIs) used for thyroid cancer treatment. It's like comparing different desert routes, each offering its own advantages and disadvantages in navigating the challenges of thyroid cancer. Researchers reviewed multiple studies to assess the efficacy and safety of four TKIs: sorafenib, lenvatinib, vandetanib, and cabozantinib. The meta-analysis provides a comprehensive overview of the current evidence on TKIs for thyroid cancer, highlighting both the potential benefits and the need to carefully consider the associated side effects.

Understanding the Landscape of Thyroid Cancer Treatment

This study provides valuable insights into the evolving landscape of thyroid cancer treatment. It helps to understand the strengths and limitations of different TKIs, enabling healthcare providers to make more informed decisions about treatment options. It's like having a detailed map of the desert, allowing us to better understand the terrain and choose the best path forward for each patient.

A New Frontier in Thyroid Cancer Treatment

This study highlights the potential of TKIs for thyroid cancer treatment, offering new hope for patients facing this challenge. It underscores the importance of ongoing research and development to improve treatment options and minimize side effects. It's like discovering a new oasis in the desert of thyroid cancer treatment, providing a source of hope and a path to potentially better outcomes.

Dr.Camel's Conclusion

This meta-analysis offers a comprehensive look at the efficacy and safety of TKIs for thyroid cancer treatment. It highlights the need for careful consideration of the individual needs of each patient and the importance of ongoing research to develop more effective and less toxic therapies. It's like navigating a complex desert landscape, where finding the right path to healing requires a balance of knowledge, experience, and innovation.
Date :
  1. Date Completed 2021-10-14
  2. Date Revised 2022-03-25
Further Info :

Pubmed ID

32814730

DOI: Digital Object Identifier

10.1507/endocrj.EJ20-0171

Related Literature

Article Analysis
・Effects of cabozantinib (thyroid cancer)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.